27. Biovigilance

  1. René R. P. De Vries MD4 and
  2. Jean-Claude Faber MD5
  1. Jerry A. Holmberg PhD1,
  2. Matthew J. Kuehnert MD2 and
  3. D. Michael Strong PhD3

Published Online: 6 AUG 2012

DOI: 10.1002/9781118338179.ch27

Hemovigilance: An Effective Tool for Improving Transfusion Safety

Hemovigilance: An Effective Tool for Improving Transfusion Safety

How to Cite

Holmberg, J. A., Kuehnert, M. J. and Strong, D. M. (2012) Biovigilance, in Hemovigilance: An Effective Tool for Improving Transfusion Safety (eds R. R. P. De Vries and J.-C. Faber), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781118338179.ch27

Editor Information

  1. 4

    Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands

  2. 5

    Blood Transfusion Service of the Luxembourg Red Cross, Luxembourg

Author Information

  1. 1

    Scientific Affairs, Novartis Vaccines and Diagnostics Inc., Emeryville, CA, USA

  2. 2

    Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA

  3. 3

    Department of Orthopaedics and Sports Medicine, University of Washington School of Medicine, Seattle, WA, USA

Publication History

  1. Published Online: 6 AUG 2012
  2. Published Print: 29 AUG 2012

ISBN Information

Print ISBN: 9780470655276

Online ISBN: 9781118338179



  • biovigilance;
  • definition of biovigilance and surveillance;
  • monitoring of blood and blood components, and adverse events;
  • surveillance of common events of interest, comprehensive;
  • biologic-based products/technologies, an inherent risks;
  • biovigilance in the United States;
  • coordinating public health and approach to risk;
  • AEs and HCT/P in the US, HCT/Ps undergo processing to disinfect;
  • transmission of infectious agents, known/unknown from organ donor;
  • emerging threat assessment


This chapter contains sections titled:

  • Definition of biovigilance and surveillance

  • Background of need

  • Coordinating public health and approach to risk

  • Biovigilance in the United States: Efforts to bridge a critical gap in patient safety and donor health

  • Development of Vigilance and Surveillance (V&S) systems for HCT/P and organs

  • Emerging threat assessment: Looking to the future and beyond known transfusion/transplantation-related events

  • Mandates for a Comprehensive Biovigilance Program and Future Challenges

  • Conclusions

  • References